298 related articles for article (PubMed ID: 22052418)
1. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
Terpos E; Christoulas D; Katodritou E; Bratengeier C; Gkotzamanidou M; Michalis E; Delimpasi S; Pouli A; Meletis J; Kastritis E; Zervas K; Dimopoulos MA
Int J Cancer; 2012 Sep; 131(6):1466-71. PubMed ID: 22052418
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Terpos E; Heath DJ; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher PI
Br J Haematol; 2006 Dec; 135(5):688-92. PubMed ID: 17107351
[TBL] [Abstract][Full Text] [Related]
3. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E; Katodritou E; Tsiftsakis E; Kastritis E; Christoulas D; Pouli A; Michalis E; Verrou E; Anargyrou K; Tsionos K; Dimopoulos MA; Zervas K;
Haematologica; 2009 Mar; 94(3):372-9. PubMed ID: 19252175
[TBL] [Abstract][Full Text] [Related]
4. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
5. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
[TBL] [Abstract][Full Text] [Related]
6. High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.
Terpos E; Dimopoulos MA; Shrivastava V; Leitzel K; Christoulas D; Migkou M; Gavriatopoulou M; Anargyrou K; Hamer P; Kastritis E; Carney W; Lipton A
Leuk Res; 2010 Mar; 34(3):399-402. PubMed ID: 19781774
[TBL] [Abstract][Full Text] [Related]
7. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E; Migkou M; Christoulas D; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Iakovaki M; Panagiotidis I; Ziogas DC; Fotiou D; Kastritis E; Dimopoulos MA
Blood Cancer J; 2016 May; 6(5):e428. PubMed ID: 27232930
[TBL] [Abstract][Full Text] [Related]
8. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
9. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
Lee SE; Min CK; Yahng SA; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Eur J Haematol; 2011 Jan; 86(1):83-6. PubMed ID: 20946110
[TBL] [Abstract][Full Text] [Related]
10. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
Terpos E; Dimopoulos MA; Sezer O
Leukemia; 2007 Sep; 21(9):1875-84. PubMed ID: 17611556
[TBL] [Abstract][Full Text] [Related]
11. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
Front Immunol; 2018; 9():2467. PubMed ID: 30410490
[TBL] [Abstract][Full Text] [Related]
12. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
13. Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.
Walter-Croneck A; Grzasko N; Soroka-Wojtaszko M; Jurczyszyn A; Torosian T; Rymko M; Nowicki A; Druzd-Sitek A; Lech-Maranda E; Madro E; Zielinska P; Grygoruk-Wisniowska I; Blonska D; Usnarska-Zubkiewicz L; Potoczek S; Iskierka E; Masternak A; Holojda J; Dawidowska D; Gawron L; Barchnicka A; Olszewska-Szopa M; Rybicka M; Gontarska A; Jachalska A; Rzepecki P; Subocz E; Boguradzki P; Charlinski G; Dzierzak-Mietla M; Wisniewska-Piaty K; Swistek W; Kopacz A; Blajer-Olszewska B; Swiderska A; Dmoszynska A
Leuk Res; 2014 Jul; 38(7):788-94. PubMed ID: 24862794
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
16. Response to bortezomib and activation of osteoblasts in multiple myeloma.
Zangari M; Yaccoby S; Cavallo F; Esseltine D; Tricot G
Clin Lymphoma Myeloma; 2006 Sep; 7(2):109-14. PubMed ID: 17026821
[TBL] [Abstract][Full Text] [Related]
17. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
Terpos E; Kastritis E; Christoulas D; Gkotzamanidou M; Eleutherakis-Papaiakovou E; Kanellias N; Papatheodorou A; Dimopoulos MA
Ann Oncol; 2012 Oct; 23(10):2681-2686. PubMed ID: 22492699
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
19. Impact of bortezomib on bone health in myeloma: a review of current evidence.
Zangari M; Terpos E; Zhan F; Tricot G
Cancer Treat Rev; 2012 Dec; 38(8):968-80. PubMed ID: 22226939
[TBL] [Abstract][Full Text] [Related]
20. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
